课题基金 / 基金详情

Southwest Oncology Group U10 Member Site

Southwest Oncology Group U10 Member Site
西南肿瘤学组 U10 会员网站
批准号:
8410591
负责人:
LAWRENCE E FLAHERTY
金额:
$33.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-01-01 至 2014-12-31

项目摘要

项目成果

LAWRENCE E FLAHERTY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Wayme State University (WSU) has been an active institutional member of the Southwest Oncology Group (SWOG) since 1972. We have enrolled over 4500 patients onto clinical trials and remain one of the highest contributing institutions by meeting and exceeding patient accrual goals in a continuous and consistent manner. Over the years, faculty members have played an important role in support of SWOG, providing leadership in both the administrative and scientific functions of the group. The clinical research program in cancer at WSU is organized along the lines of multidisciplinary disease oriented studies and in a manner which resembles the organ committee orientation of SWOG. Our faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment toward these areas of research. Accordingly, the translation of ideas into SWOG studies, and the incorporation of SWOG studies and those bf NCI designated high priority trials into WSU treatment priorities, are easily facilitated. Additionally, the unique demographics of our region and the cancer center commitment to the inclusion of minorities and women into clinical trials can be clearly identified in our recruitment of minorities (24%) and women (52%) into SWOG clinical trials. Our cancer center mission statement states that we are "a unique, urban-based center of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer". This mission remains consistent with the overall mission of the SWOG cooperative group, enhancing our continued success in this research collaboration. In this challenging economic time and as a U10 member, it is acknowledged that monetary resources are not sufficient to completely fund the challenging work that we do. Despite this, it is the goal of WSU to continue our support at the level we are currently involved. Additionally, we will facilitate the education and success in our next generation of investigators, leading by example and commitment. Lawrence Flaherty, MD has been a SWOG member since 1986 and Co-Chairman of the SWOG Melanoma Committee and Co-Chair of the SWOG Melanoma Working Group since 1988 and 1990, respectively. As the Institutional PI since 1996 he has maintained the prominence and excellence of WSU as a SWOG full member institution.
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/bf00173789
发表时间: 1984
期刊: Investigational new drugs
影响因子: 3.4
作者: [Knight3rd,WA, O'Bryan,RM, Samal,B, Costanzi,JJ]
通讯作者: Costanzi,JJ
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
达卡巴嗪和门诊白细胞介素 2 治疗转移性恶性黑色素瘤:西南肿瘤组 II 期试验。
DOI: 10.1093/jnci/84.11.893
发表时间: 1992
期刊: Journal of the National Cancer Institute
影响因子: --
作者: [Flaherty,LE, Liu,PY, Fletcher,WS, Goodwin,JW, Balcerzak,SP, Daniels,D, Stephens,RL, Sondak,VK]
通讯作者: Sondak,VK
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
治疗胃腺癌的药物组合:一项随机西南肿瘤组研究。
DOI: 10.1200/jco.1984.2.5.420
发表时间: 1984
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者: [Panettiere,FJ, Haas,C, McDonald,B, Costanzi,JJ, Talley,RW, Athens,J, Oishi,N, Heilbrun,LK, Chen,TT]
通讯作者: Chen,TT
A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
静脉注射 6-硫鸟嘌呤 (NSC-752) 治疗多发性骨髓瘤的 A 期 II 研究。
DOI: 10.1007/bf00171990
发表时间: 1990
期刊: Investigational new drugs
影响因子: 3.4
作者: [Edelstein,MB, Crowley,JJ, Valeriote,FA, Bonnet,JD, Carden,JO, Khanna,RC, Salmon,SE, Ungerleider,JS]
通讯作者: Ungerleider,JS
20
    NCI National Clinical Trials Network – Network Lead Academic Participating Site
    • 批准号:
      10357935
    • 项目类别:
    • 资助金额:
      $51.87万
    • 财政年份:
      2019
    • 负责人:
      LAWRENCE E FLAHERTY
    • 依托单位:
    NCI National Clinical Trials Network – Network Lead Academic Participating Site
    • 批准号:
      9886223
    • 项目类别:
    • 资助金额:
      $50.54万
    • 财政年份:
      2019
    • 负责人:
      LAWRENCE E FLAHERTY
    • 依托单位:
    NCI National Clinical Trials Network – Network Lead Academic Participating Site
    • 批准号:
      10579865
    • 项目类别:
    • 资助金额:
      $47.16万
    • 财政年份:
      2019
    • 负责人:
      LAWRENCE E FLAHERTY
    • 依托单位:
    NCI National Clinical Trials Network-Network Lead Academic Participating Site
    • 批准号:
      8842111
    • 项目类别:
    • 资助金额:
      $60.27万
    • 财政年份:
      2014
    • 负责人:
      LAWRENCE E FLAHERTY
    • 依托单位:
    海外基金